Revvity (NYSE:RVTY) Rating Increased to Overweight at Barclays

Revvity (NYSE:RVTY) was upgraded by analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm currently has a $140.00 price objective on the stock, up from their prior price objective of $125.00. Barclays‘s price objective would suggest a potential upside of 16.46% from the stock’s current price.

RVTY has been the topic of a number of other reports. JPMorgan Chase & Co. boosted their price target on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Wells Fargo & Company initiated coverage on shares of Revvity in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target for the company. Leerink Partners started coverage on Revvity in a research report on Monday, July 8th. They set an “outperform” rating and a $125.00 price objective on the stock. Leerink Partnrs upgraded Revvity to a “strong-buy” rating in a report on Monday, July 8th. Finally, Citigroup upped their price target on Revvity from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.53.

Revvity Stock Down 3.3 %

Shares of RVTY opened at $120.21 on Tuesday. Revvity has a 12-month low of $79.50 and a 12-month high of $128.15. The firm has a market cap of $14.83 billion, a P/E ratio of 99.35, a price-to-earnings-growth ratio of 3.35 and a beta of 1.05. The company’s 50-day moving average price is $121.60 and its 200 day moving average price is $112.82. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, July 29th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The firm had revenue of $691.70 million for the quarter, compared to analyst estimates of $690.33 million. During the same period in the prior year, the business posted $1.21 EPS. The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. On average, sell-side analysts forecast that Revvity will post 4.75 earnings per share for the current year.

Insider Transactions at Revvity

In related news, insider Tajinder S. Vohra sold 2,153 shares of Revvity stock in a transaction on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the sale, the insider now directly owns 23,960 shares in the company, valued at $2,925,276.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Revvity news, insider Tajinder S. Vohra sold 2,154 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,392,237.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tajinder S. Vohra sold 2,153 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $122.09, for a total transaction of $262,859.77. Following the transaction, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,807 shares of company stock worth $937,576. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Revvity

A number of large investors have recently bought and sold shares of RVTY. Drake & Associates LLC raised its holdings in shares of Revvity by 13.2% in the third quarter. Drake & Associates LLC now owns 4,976 shares of the company’s stock valued at $636,000 after buying an additional 580 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Revvity during the 3rd quarter valued at approximately $277,000. Creative Planning lifted its position in Revvity by 2.3% during the 3rd quarter. Creative Planning now owns 20,308 shares of the company’s stock worth $2,594,000 after acquiring an additional 451 shares during the period. CX Institutional grew its stake in shares of Revvity by 1.1% in the 3rd quarter. CX Institutional now owns 7,984 shares of the company’s stock valued at $1,020,000 after purchasing an additional 86 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Revvity by 2.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 9,088 shares of the company’s stock valued at $1,161,000 after purchasing an additional 193 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.